Shares of ANI Pharmaceuticals Inc (NASDAQ:ANIP) have been assigned a consensus recommendation of “Buy” from the seven ratings firms that are presently covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and three have issued a buy rating on the company. The average 1 year price target among analysts that have covered the stock in the last year is $71.00.
ANIP has been the subject of several recent analyst reports. BidaskClub cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, December 21st. Canaccord Genuity set a $75.00 price objective on shares of ANI Pharmaceuticals and gave the company a “buy” rating in a research note on Saturday, December 9th. ValuEngine upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, November 25th. Zacks Investment Research upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating and set a $71.00 price objective for the company in a research note on Tuesday, November 7th. Finally, TheStreet upgraded shares of ANI Pharmaceuticals from a “c+” rating to a “b” rating in a research note on Thursday, November 16th.
Large investors have recently bought and sold shares of the business. BNP Paribas Arbitrage SA increased its holdings in ANI Pharmaceuticals by 44.6% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,152 shares of the specialty pharmaceutical company’s stock valued at $101,000 after acquiring an additional 664 shares in the last quarter. Bank of Montreal Can increased its holdings in ANI Pharmaceuticals by 681.8% during the 4th quarter. Bank of Montreal Can now owns 2,408 shares of the specialty pharmaceutical company’s stock valued at $156,000 after acquiring an additional 2,100 shares in the last quarter. SG Americas Securities LLC purchased a new position in ANI Pharmaceuticals during the 3rd quarter valued at about $197,000. Louisiana State Employees Retirement System purchased a new position in ANI Pharmaceuticals during the 4th quarter valued at about $251,000. Finally, Violich Capital Management Inc. purchased a new position in ANI Pharmaceuticals during the 3rd quarter valued at about $217,000. Hedge funds and other institutional investors own 55.05% of the company’s stock.
ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Thursday, November 2nd. The specialty pharmaceutical company reported $1.11 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.99 by $0.12. ANI Pharmaceuticals had a net margin of 4.45% and a return on equity of 22.40%. The firm had revenue of $48.16 million during the quarter, compared to analysts’ expectations of $48.12 million. During the same quarter last year, the business earned $1.09 earnings per share. The business’s revenue for the quarter was up 25.0% compared to the same quarter last year. research analysts forecast that ANI Pharmaceuticals will post 3.59 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This report was reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of United States & international copyright & trademark legislation. The correct version of this report can be viewed at https://www.americanbankingnews.com/2018/01/19/ani-pharmaceuticals-inc-anip-given-consensus-recommendation-of-buy-by-analysts.html.
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.